Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Updates on the Management of Patients With Lymphomas During the COVID-19 Pandemic
  • CME
  • CE

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: October 19, 2021 Expiration: October 18, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
John Allan, MD
Sandra E. Kurtin, PhD, ANP-C, AOCN

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide appropriate management strategies for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic
  • Select or modify treatment based on the available clinical data, guidelines, and expert recommendations to reduce office visits and maintain efficacy
  • Integrate telemedicine for routine follow-up visits, as appropriate
  • Manage adverse events associated with treatment approaches for MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies to ensure treatment compliance as well as improved clinical outcomes and quality of life
  • Provide counsel to patients and caregivers based on best practices for infection control

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed that he has received consulting fees from AbbVie, ADC Therapeutics, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics, and TG Therapeutics; funds for research support from Genentech, Janssen, and TG Therapeutics; and fees for non-CME/CE services from AbbVie, BeiGene, Janssen, and Pharmacyclics.
Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed that she has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Epizyme, Incyte, and Pharmacyclics.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for hematologists, oncologists, nurses, pharmacists, and advanced practitioners in hematology/oncology who care for patients with MCL, MZL, CLL/SLL, or WM receiving targeted therapeutics as part of in-home care.

Goal

The goal of this activity is to provide a comprehensive, agile, and highly accessible educational curriculum designed to improve oncology healthcare professionals’ competence in providing effective personalized care for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-223-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 19, 2021, through October 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Updates on the Management of Patients With Lymphomas During the COVID-19 Pandemic
  • CME
  • CE

Loading...
Watch this interactive webcast of a live CCO webinar tailored to the multidisciplinary oncology team to gain expert perspectives on the care of patients with lymphomas during the COVID-19 pandemic.
John Allan, MD
Sandra E. Kurtin, PhD, ANP-C, AOCN
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: October 19, 2021 Expiration: October 18, 2022

Related Content

Commentary from Dr Julie M. Vose on how to select therapy for patients with diffuse large B-cell lymphoma, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 1, 2021

person default Ashley Leak Bryant, PhD, RN, OCN, FAAN Sara Tinsley, PhD, APRN, AOCN Released: November 29, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue